Author: admin

“Anti-CD152 Antibody Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anti-CD152 Antibody Market.

The Anti-CD152 Antibody Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Anti-CD152 Antibody Pipeline Report:

• Companies across the globe are diligently working toward developing novel Anti-CD152 Antibody treatment therapies with a considerable amount of success over the years.

• Anti-CD152 Antibody companies working in the treatment market are RemeGen, Caribou Biosciences, Precision Biosciences, TG Therapeutics, Xencor, Horizon Therapeutics, Morphosys, and others, are developing therapies for the Anti-CD152 Antibody treatment

• Emerging Anti-CD152 Antibody therapies in the different phases of clinical trials are- RC58, CB-010, PBCAR19B, TG-1801, Obexelimab (XmAb5871), Inebilizumab, Tafasitamab, and others are expected to have a significant impact on the Anti-CD152 Antibody market in the coming years.

• In May 2024, ADC Therapeutics released topline Phase II data for its Anti-CD152 Antibody drug conjugate Zynlonta (loncastuximab tesirine-lpyl), showing high treatment response rates in patients with relapsed or refractory marginal zone lymphoma. The early data, from 15 evaluable patients out of 50 enrolled in the single-arm, open-label mid-stage study, revealed that 13 patients achieved complete response (CR) and one patient demonstrated partial response. All responses were maintained until the data cut-off.

Anti-CD152 Antibody Overview

Anti-CD152 antibody is a type of immunotherapy that targets CD152, also known as CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4)—a protein receptor found on T cells. CTLA-4 acts as an immune checkpoint that downregulates immune responses. By blocking CTLA-4, anti-CD152 antibodies help enhance T cell activation and boost the immune system’s ability to attack cancer cells or fight infections. These antibodies are being explored in cancer immunotherapy and autoimmune disease treatment, aiming to modulate immune function either by enhancing it (in cancer) or suppressing it (in autoimmune disorders), depending on the therapeutic context.

Get a Free Sample PDF Report to know more about Anti-CD152 Antibody Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/anti-cd152-antibody-pipeline-insight

Emerging Anti-CD152 Antibody Drugs Under Different Phases of Clinical Development Include:

• RC58: RemeGen

• CB-010: Caribou Biosciences

• PBCAR19B: Precision Biosciences

• TG-1801: TG Therapeutics

• Obexelimab (XmAb5871): Xencor

• Inebilizumab: Horizon Therapeutics

• Tafasitamab: Morphosys

Anti-CD152 Antibody Pipeline Therapeutics Assessment

• Anti-CD152 Antibody Assessment by Product Type

• Anti-CD152 Antibody By Stage and Product Type

• Anti-CD152 Antibody Assessment by Route of Administration

• Anti-CD152 Antibody By Stage and Route of Administration

• Anti-CD152 Antibody Assessment by Molecule Type

• Anti-CD152 Antibody by Stage and Molecule Type

DelveInsight’s Anti-CD152 Antibody Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Anti-CD152 Antibody product details are provided in the report. Download the Anti-CD152 Antibody pipeline report to learn more about the emerging Anti-CD152 Antibody therapies

Some of the key companies in the Anti-CD152 Antibody Therapeutics Market include:

Key companies developing therapies for Anti-CD152 Antibody are – TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and others.

Anti-CD152 Antibody Pipeline Analysis:

The Anti-CD152 Antibody pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Anti-CD152 Antibody with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anti-CD152 Antibody Treatment.

• Anti-CD152 Antibody key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Anti-CD152 Antibody Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anti-CD152 Antibody market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Anti-CD152 Antibody drugs and therapies

Anti-CD152 Antibody Pipeline Market Drivers

• High incidence rates of B-cell malignancies, rise in healthcare investment (by the government and private organizations) are some of the important factors that are fueling the Anti-CD152 Antibody Market.

Anti-CD152 Antibody Pipeline Market Barriers

• However, side effects associated with the Treatment, high cost associated with the Treatment and other factors are creating obstacles in the Anti-CD152 Antibody Market growth.

Scope of Anti-CD152 Antibody Pipeline Drug Insight

• Coverage: Global

• Key Anti-CD152 Antibody Companies: RemeGen, Caribou Biosciences, Precision Biosciences, TG Therapeutics, Xencor, Horizon Therapeutics, Morphosys, and others

• Key Anti-CD152 Antibody Therapies: RC58, CB-010, PBCAR19B, TG-1801, Obexelimab (XmAb5871), Inebilizumab, Tafasitamab, and others

• Anti-CD152 Antibody Therapeutic Assessment: Anti-CD152 Antibody current marketed and Anti-CD152 Antibody emerging therapies

• Anti-CD152 Antibody Market Dynamics: Anti-CD152 Antibody market drivers and Anti-CD152 Antibody market barriers

Request for Sample PDF Report for Anti-CD152 Antibody Pipeline Assessment and clinical trials

Table of Contents

1. Anti-CD152 Antibody Report Introduction

2. Anti-CD152 Antibody Executive Summary

3. Anti-CD152 Antibody Overview

4. Anti-CD152 Antibody- Analytical Perspective In-depth Commercial Assessment

5. Anti-CD152 Antibody Pipeline Therapeutics

6. Anti-CD152 Antibody Late Stage Products (Phase II/III)

7. Anti-CD152 Antibody Mid Stage Products (Phase II)

8. Anti-CD152 Antibody Early Stage Products (Phase I)

9. Anti-CD152 Antibody Preclinical Stage Products

10. Anti-CD152 Antibody Therapeutics Assessment

11. Anti-CD152 Antibody Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Anti-CD152 Antibody Key Companies

14. Anti-CD152 Antibody Key Products

15. Anti-CD152 Antibody Unmet Needs

16 . Anti-CD152 Antibody Market Drivers and Barriers

17. Anti-CD152 Antibody Future Perspectives and Conclusion

18. Anti-CD152 Antibody Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anti-CD152 Antibody Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Precision Biosciences, TG Therapeutics, RemeGen, Caribou Biosciences

“CRISPR Therapies Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CRISPR Therapies Market.

The CRISPR Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the CRISPR Therapies Pipeline Report:

• Companies across the globe are diligently working toward developing novel CRISPR Therapies treatment therapies with a considerable amount of success over the years.

• CRISPR Therapies companies working in the treatment market are Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others, are developing therapies for the CRISPR Therapies treatment

• Emerging CRISPR Therapies therapies in the different phases of clinical trials are- BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others are expected to have a significant impact on the CRISPR Therapies market in the coming years.

• In May 2025, Researchers at the University of Minnesota have completed the first human clinical trial using a CRISPR/Cas9 gene-editing method aimed at boosting the immune system’s ability to combat advanced gastrointestinal (GI) cancers. The findings, recently published in Lancet Oncology, demonstrate promising safety and potential effectiveness of the therapy. In this study, the team employed CRISPR/Cas9 to modify tumor-infiltrating lymphocytes (TILs), a type of immune cell. By disabling the CISH gene, the modified TILs showed an improved capacity to identify and attack cancer cells.

• In January 2025, Scientists at the Experimental and Clinical Research Center (ECRC) in Berlin are advancing a targeted gene-editing therapy for muscular dystrophy. Preclinical studies conducted by the Spuler Lab, recently published in Nature Communications, have laid the groundwork for upcoming first-in-human clinical trials. The ECRC, a collaboration between the Max Delbrück Center and Charité – Universitätsmedizin Berlin, has created a promising gene-editing strategy aimed at restoring the function of a key protein vital for muscle repair and regeneration in patients suffering from muscular dystrophy.

CRISPR Therapies Overview

CRISPR therapies are a type of gene-editing treatment that use the CRISPR-Cas9 technology to precisely modify DNA within cells. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) allows scientists to target and correct faulty genes responsible for various genetic disorders. These therapies hold promise for treating conditions like sickle cell anemia, cancer, and certain inherited diseases by either repairing or disabling the problematic gene. CRISPR-based therapies are still largely in clinical trial phases but represent a revolutionary approach to personalized and potentially curative medicine.

Get a Free Sample PDF Report to know more about CRISPR Therapies Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/crispr-therapies-pipeline-insight

Emerging CRISPR Therapies Drugs Under Different Phases of Clinical Development Include:

• BEAM-301: Beam Therapeutics

• TNG260: Tango Therapeutics

• CTX 130: CRISPR therapeutics

• CB-010: Caribou Biosciences, Inc.

• KSQ-4279: KSQ Therapeutics

• NTLA-2002: Intellia Therapeutics, Inc.

• LBP-EC01: Locus Biosciences

• CTX001: CRISPR Therapeutic

CRISPR Therapies Route of Administration

CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical.

• Molecule Type

CRISPR Therapies Molecule Type

CRISPR Therapies Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

• Product Type

CRISPR Therapies Pipeline Therapeutics Assessment

• CRISPR Therapies Assessment by Product Type

• CRISPR Therapies By Stage and Product Type

• CRISPR Therapies Assessment by Route of Administration

• CRISPR Therapies By Stage and Route of Administration

• CRISPR Therapies Assessment by Molecule Type

• CRISPR Therapies by Stage and Molecule Type

DelveInsight’s CRISPR Therapies Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further CRISPR Therapies product details are provided in the report. Download the CRISPR Therapies pipeline report to learn more about the emerging CRISPR Therapies therapies

Some of the key companies in the CRISPR Therapies Therapeutics Market include:

Key companies developing therapies for CRISPR Therapies are – eGenesis, Intellia Therapeutics, Editas Medicine, Caribou Biosciences, Inscripta, Synthego, Inari, Ligandal, CRISPR Therapeutics, Mammoth Biosciences, Poseida Therapeutics, Beam Therapeutics, Pairwise, Sherlock Biosciences, and others

CRISPR Therapies Pipeline Analysis:

The CRISPR Therapies pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of CRISPR Therapies with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CRISPR Therapies Treatment.

• CRISPR Therapies key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• CRISPR Therapies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CRISPR Therapies market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about CRISPR Therapies drugs and therapies

CRISPR Therapies Pipeline Market Drivers

• New drugs are discovered employing the novel ways to treat diseases, CRISPR/Cas9 provides extensive opportunities for programmable gene editing are some of the important factors that are fueling the CRISPR Therapies Market.

CRISPR Therapies Pipeline Market Barriers

• However, unwanted immune responses, off-target effects, CRISPR has tangible progress for localized administration and other factors are creating obstacles in the CRISPR Therapies Market growth.

Scope of CRISPR Therapies Pipeline Drug Insight

• Coverage: Global

• Key CRISPR Therapies Companies: Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others

• Key CRISPR Therapies Therapies: BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others

• CRISPR Therapies Therapeutic Assessment: CRISPR Therapies current marketed and CRISPR Therapies emerging therapies

• CRISPR Therapies Market Dynamics: CRISPR Therapies market drivers and CRISPR Therapies market barriers

Request for Sample PDF Report for CRISPR Therapies Pipeline Assessment and clinical trials

Table of Contents

1. CRISPR Therapies Report Introduction

2. CRISPR Therapies Executive Summary

3. CRISPR Therapies Overview

4. CRISPR Therapies- Analytical Perspective In-depth Commercial Assessment

5. CRISPR Therapies Pipeline Therapeutics

6. CRISPR Therapies Late Stage Products (Phase II/III)

7. CRISPR Therapies Mid Stage Products (Phase II)

8. CRISPR Therapies Early Stage Products (Phase I)

9. CRISPR Therapies Preclinical Stage Products

10. CRISPR Therapies Therapeutics Assessment

11. CRISPR Therapies Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. CRISPR Therapies Key Companies

14. CRISPR Therapies Key Products

15. CRISPR Therapies Unmet Needs

16 . CRISPR Therapies Market Drivers and Barriers

17. CRISPR Therapies Future Perspectives and Conclusion

18. CRISPR Therapies Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Crispr Therapeutics Products 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | eGenesis, Intellia Therapeutics, Editas Medicine, Caribou Biosciences, Inscripta, Synthego

According to DelveInsight’s analysis, The increasing demand for cataract surgery devices is largely driven by the rising prevalence of cataracts and vision impairment, along with the growing incidence of lifestyle-related conditions like hypertension and diabetes that contribute to cataract development. Additionally, the expanding elderly population, ongoing research and development, and technological advancements in product innovation are key factors supporting the market’s positive growth outlook between 2024 and 2030.

DelveInsight’s “Cataract Surgery Devices Market Insights, Competitive Landscape and Market Forecast-2030” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Cataract Surgery Devices companies actively working in the market.

To know more about why North America is leading the market growth in the Cataract Surgery Devices market, get a snapshot of the report Cataract Surgery Devices Market Trends

Cataract Surgery Devices Overview

Cataract surgery devices are specialized medical instruments and tools used to perform cataract surgery, a procedure to remove a clouded lens (cataract) from the eye and replace it with an artificial intraocular lens (IOL). These devices include phacoemulsification machines, IOLs, surgical lasers, ophthalmic viscoelastic devices (OVDs), and other instruments essential for precise and safe surgery. They help restore vision, improve quality of life, and are widely used due to the high prevalence of cataracts, especially among the aging population.

DelveInsight Analysis: The cataract surgery devices market was valued at approximately USD 7.73 billion in 2023 and is projected to grow at a CAGR of 5.50% from 2024 to 2030, reaching an estimated USD 10.66 billion by the end of the forecast period.

Cataract Surgery Devices Market Insights

Geographically, North America is projected to dominate the cataract surgery devices market in 2023, primarily due to the increasing cases of cataracts and vision-related disorders. Contributing risk factors such as diabetes, hypertension, and obesity are also prevalent in the region. Additionally, the expanding elderly population—more prone to cataracts—and ongoing technological advancements in device development are key elements supporting the market’s growth across North America.

To read more about the latest highlights related to Cataract Surgery Devices, get a snapshot of the key highlights entailed in the Cataract Surgery Devices

https://www.delveinsight.com/report-store/cataract-surgery-devices-market

Recent Developments in the Cataract Surgery Devices Market Report

• In July 2024, Oertli Instrumente AG received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Faros anterior cataract surgery system. This high-performance surgical platform is designed to support procedures involving cataracts, vitreoretinal conditions, and glaucoma. It features sophisticated fluidics and vacuum control technologies, enabling enhanced surgical precision and smooth adaptation to different levels of cataract density.

• In June 2024, Alcon obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS). These systems are designed to provide improved precision during cataract surgeries involving vitreoretinal procedures.

• In April 2023, Bausch + Lomb Corporation has introduced the StableVisc™ cohesive ophthalmic viscosurgical device (OVD) and the TotalVisc™ Viscoelastic System in the U.S. These products are developed to preserve space in the eye’s anterior chamber, aiding in the efficient removal and replacement of the clouded natural lens during cataract surgery.

• Thus, owing to such developments in the market, rapid growth will be observed in the Cataract Surgery Devices market during the forecast period

Key Players in the Cataract Surgery Devices Market

Some of the key market players operating in the Cataract Surgery Devices market include- Alcon Inc., Johnson & Johnson Services, Inc., NIDEK CO., LTD., ZEISS Group, Bausch Health Companies Inc., Ziemer Ophthalmic Systems AG, Abbott Laboratories, HOYA Corporation, Aurolab, Hanita Lenses Ltd, Topcon Corporation, STAAR SURGICAL, Bohus BioTech AB, Eyekon Medical, CIMA Technology Inc., Medisonic Equipments Pvt. Ltd., Opthalmika Ltd, Lumenis Be Ltd., Essilor International, Oertli Instrumente AG, and others.

Which MedTech key players in the Cataract Surgery Devices market are set to emerge as the trendsetter explore @ Key Cataract Surgery Devices Companies

Analysis on the Cataract Surgery Devices Market Landscape

Within the product segment of the cataract surgery devices market, femtosecond lasers are anticipated to hold a substantial share throughout the forecast period, fueled by the rising volume of cataract surgeries worldwide. Data from the European Commission in 2023 highlights that cataract surgery was the most frequently performed surgical procedure, with 4.32 million surgeries carried out across Europe in 2021.

Key market leaders are concentrating on developing and commercializing advanced femtosecond lasers to enhance surgical accuracy, safety, and patient results. For example, in April 2023, Johnson & Johnson MedTech obtained FDA 510(k) clearance for its ELITA Femtosecond Laser system. This system features low energy per pulse and an ultra-fast laser repetition rate, aiming to reduce complications and improve visual recovery and patient outcomes. Innovations like these are anticipated to fuel considerable growth in the femtosecond laser segment, supporting the broader expansion of the cataract surgery devices market.

Scope of the Cataract Surgery Devices Market Report

• Coverage: Global

• Study Period: 2021–2030

• Cataract Surgery Devices Market Segmentation By Product Type: Phacoemulsification Systems, Femtosecond Lasers, Intraocular Lenses, Ophthalmic Viscosurgical Devices, and Others

• Cataract Surgery Devices Market Segmentation By End-User: Hospitals and Specialty Clinics

• Cataract Surgery Devices Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World

• Key Cataract Surgery Devices Companies: Alcon Inc., Johnson & Johnson Services, Inc., NIDEK CO., LTD., ZEISS Group, Bausch Health Companies Inc., Ziemer Ophthalmic Systems AG, Abbott Laboratories, HOYA Corporation, Aurolab, Hanita Lenses Ltd, Topcon Corporation, STAAR SURGICAL, Bohus BioTech AB, Eyekon Medical, CIMA Technology Inc., Medisonic Equipments Pvt. Ltd., Opthalmika Ltd, Lumenis Be Ltd., Essilor International, Oertli Instrumente AG, and others

• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Interested in knowing how the Cataract Surgery Devices market will grow by 2030? Click to get a snapshot of the Cataract Surgery Devices Market Analysis

Table of Contents

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Global Cataract Surgery Devices Market to grow at a CAGR of 5.50% by 2030, Evaluates DelveInsight | Alcon, Johnson & Johnson, NIDEK, ZEISS Group, Bausch Health, Ziemer Ophthalmic Systems AG, Abbott

“Acquired Hemophilia A Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acquired Hemophilia A Market.

The Acquired Hemophilia A Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Acquired Hemophilia A Pipeline Report

• Companies across the globe are diligently working toward developing novel Acquired Hemophilia A treatment therapies with a considerable amount of success over the years. Acquired Hemophilia A Key players such as – Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others are developing therapies for the Acquired Hemophilia A treatment

• Acquired Hemophilia A Emerging therapies such as – BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran, PF-06, and others are expected to have a significant impact on the Acquired Hemophilia A market in the coming years.

• In February 2025, Researchers have documented two cases where factor VIII inhibitors were successfully eliminated in patients with acquired hemophilia A treated with rituximab. Published in Hematology, these reports highlighted rituximab as both safe and effective, potentially serving as a first-line therapy for acquired hemophilia A. The authors explained, “Rituximab, a monoclonal antibody targeting CD20-positive B cells, shows promise in treating acquired hemophilia by decreasing the production of autoantibodies against factor VIII.” They also noted that current guidelines recommend rituximab as a first-line option primarily for patients with poor prognosis or those who cannot tolerate standard first-line treatments.

• In July 2024, Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced Pfizer Inc.’s positive topline results from the Phase 3 AFFINE trial (NCT04370054). The study evaluates giroctocogene fitelparvovec, an investigational gene therapy co-developed by Sangamo and licensed to Pfizer for treating adults with moderately severe to severe hemophilia A.

• In May 2024, Danish pharmaceutical firm Novo Nordisk announced key findings from FRONTIER II, a Phase IIIa study evaluating subcutaneous Mim8 for haemophilia A treatment.

Acquired Hemophilia A Overview

Acquired Hemophilia A is a rare autoimmune bleeding disorder in which the body produces antibodies (autoantibodies) that attack clotting factor VIII, a protein essential for blood clotting. Unlike congenital hemophilia, it develops later in life and is not inherited. This condition can lead to spontaneous, severe bleeding into the skin, muscles, or internal organs, even in individuals with no prior history of bleeding disorders. It is often associated with other conditions such as autoimmune diseases, cancer, or pregnancy, but can also occur without a known cause. Prompt diagnosis and treatment are essential to manage bleeding and control the immune response.

To know more about the Acquired Hemophilia A pipeline report, click here:

https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight

Acquired Hemophilia A Pipeline Therapies along with Key Players:

• BBM-H901: Belief Biomed

• ISU304: ISU ABXIS

• TU7710: TiumBio

• BE-101: Be Biopharma

• REGV131: Regeneron Pharmaceuticals

• PF-06838435: Pfizer

• ANB-002: Biocad

• AAV5-hFIXco-Padua: CSL Behring

• VGB-R04: Shanghai Vitalgen BioPharma

• AskBio009: Baxalta

• AMA005: Amarna therapeutics

• CB 2679d-GT: Catalyst Biosciences

• FLT180a: Freeline Therapeutics

• BBM-H901: Belief BioMed

• SerpinPC: Centessa Pharmaceuticals

• Concizumab: Novo Nordisk

• Fitusiran: Sanofi

• PF-06741086: Pfizer

Acquired Hemophilia A Pipeline Therapeutics Assessment

TheAcquired Hemophilia A Pipeline report proffers an integral view of the Acquired Hemophilia A emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Acquired Hemophilia A Pipeline Clinical Phases:

DelveInsight’s Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Further Acquired Hemophilia A product details are provided in the report. Download the Acquired Hemophilia A pipeline report to learn more about the emerging Acquired Hemophilia A therapies

Some of the key companies in the Acquired Hemophilia A Therapeutics Market include:

Key companies developing therapies for Acquired Hemophilia A treatment are – Aptevo, Bayer, BioMarin, Catalyst Biosciences, CSL Behring, GC Pharma, Kaifeng Pharmaceutical, KM Biologics, LFB, Novo Nordisk, Pfizer, Octapharma, Roche, Sanofi, SinoCelltech, Spark Therapeutics, Takeda, UniQure, and others.

Acquired Hemophilia A Pipeline Analysis:

The report provides insights into

• The report provides detailed insights about companies that are developing therapies for the Acquired Hemophilia A treatment with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acquired Hemophilia A Treatment.

• Acquired Hemophilia A key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Acquired Hemophilia A Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acquired Hemophilia A market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download the Acquired Hemophilia A pipeline report to learn more about the emerging Acquired Hemophilia A therapies

Acquired Hemophilia A Pipeline Market Drivers

• Increasing prevalence of Acquired Hemophilia A disease

• Increasing R&D on identifying new therapeutic agents

Acquired Hemophilia A Pipeline Market Barriers

• High cost of Acquired Hemophilia A treatment

Scope of Acquired Hemophilia A Pipeline Drug Insight

• Coverage: Global

• Key Acquired Hemophilia A Companies: Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others

• Key Acquired Hemophilia A Therapies: BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran , PF-06, and others

• Acquired Hemophilia A Therapeutic Assessment: Acquired Hemophilia A current marketed and Acquired Hemophilia A emerging therapies

• Acquired Hemophilia A Market Dynamics: Acquired Hemophilia A market drivers and Acquired Hemophilia A market barriers

Get a Free Sample PDF Report to know more about Acquired Hemophilia A Pipeline Assessment

Table of Contents

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acquired Hemophilia A Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharmaceuticals

DelveInsight’s “Anticoagulants Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Anticoagulants, historical and forecasted epidemiology as well as the Anticoagulants market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Anticoagulants, offering comprehensive insights into the Anticoagulants revenue trends, prevalence, and treatment landscape. The report delves into key Anticoagulants statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Anticoagulants therapies. Additionally, we cover the landscape of Anticoagulants clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Anticoagulants treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Anticoagulants space.

To Know in detail about the Anticoagulants market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Anticoagulants Market Forecast

Some of the key facts of the Anticoagulants Market Report:

• The Anticoagulants market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In November 2024, Boston Scientific Corporation (NYSE: BSX) announced favorable three-year primary endpoint results from the global OPTION clinical trial evaluating the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. The study compared the device to first-line oral anticoagulation (OAC) treatments—including direct oral anticoagulants (DOACs) at 95% and warfarin at 5%—for reducing stroke risk in patients with non-valvular atrial fibrillation after cardiac ablation. These key findings were shared during a late-breaking science session at the American Heart Association’s Scientific Sessions.

• Key Anticoagulants Companies: Universitaire Ziekenhuizen KU Leuven, Takeshi Morimoto, Prothya BioSolutions, ARYx Therapeutics, Les Laboratoires, and others

• Key Anticoagulants Therapies: apixaban, Long DOAC, PPSB-SD, ATI-5923, Enoxaparin, and others

• The Anticoagulants market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Anticoagulants pipeline products will significantly revolutionize the Anticoagulants market dynamics.

• High global burden of thromboembolic disorders: Conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE) affect millions annually worldwide

• Atrial fibrillation (AF) prevalence: Over 37 million people globally suffer from AF, a major risk factor requiring anticoagulant therapy

• Rising incidence of stroke: About 15 million people suffer strokes each year, with ischemic stroke often needing anticoagulant treatment

• Elderly population at higher risk: Individuals aged 65 and above are the most frequent users of anticoagulants due to increased clotting risk

• Cancer-associated thrombosis (CAT): Patients with cancer have a 4–7 times higher risk of venous thromboembolism, requiring anticoagulant management

Anticoagulants Overview

Anticoagulants are medications that help prevent blood clots from forming or growing larger. They are often referred to as “blood thinners,” although they don’t actually thin the blood. Instead, they work by interfering with the body’s natural clotting process. Anticoagulants are commonly used to reduce the risk of stroke, heart attack, deep vein thrombosis (DVT), and pulmonary embolism (PE). Common types include warfarin, heparin, and direct oral anticoagulants (DOACs) like apixaban and rivaroxaban. While effective, they must be used carefully due to the increased risk of bleeding.

Get a Free sample for the Anticoagulants Market Forecast, Size & Share Analysis Report:

qhttps://www.delveinsight.com/report-store/anticoagulants-market

Anticoagulants Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Anticoagulants Epidemiology Segmentation:

The Anticoagulants market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Anticoagulants

• Prevalent Cases of Anticoagulants by severity

• Gender-specific Prevalence of Anticoagulants

• Diagnosed Cases of Episodic and Chronic Anticoagulants

Download the report to understand which factors are driving Anticoagulants epidemiology trends @ Anticoagulants Epidemiology Forecast

Anticoagulants Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Anticoagulants market or expected to get launched during the study period. The analysis covers Anticoagulants market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Anticoagulants Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Anticoagulants Therapies and Key Companies

• apixaban: Universitaire Ziekenhuizen KU Leuven

• Long DOAC: Takeshi Morimoto

• PPSB-SD: Prothya BioSolutions

• ATI-5923: ARYx Therapeutics

• Enoxaparin: Les Laboratoires

Discover more about therapies set to grab major Anticoagulants market share @ Anticoagulants Treatment Landscape

Anticoagulants Market Drivers

• Rising prevalence of cardiovascular diseases

• Growing aging population

• Advancements in drug formulations

• Increased awareness

• Government initiatives

Anticoagulants Market Barriers

• Risk of bleeding complications

• High cost of newer therapies

• Stringent regulatory requirements

• Lack of awareness in developing regions

• Drug interactions

Scope of the Anticoagulants Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Anticoagulants Companies: Universitaire Ziekenhuizen KU Leuven, Takeshi Morimoto, Prothya BioSolutions, ARYx Therapeutics, Les Laboratoires, and others

• Key Anticoagulants Therapies: apixaban, Long DOAC, PPSB-SD, ATI-5923, Enoxaparin, and others

• Anticoagulants Therapeutic Assessment: Anticoagulants current marketed and Anticoagulants emerging therapies

• Anticoagulants Market Dynamics: Anticoagulants market drivers and Anticoagulants market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Anticoagulants Unmet Needs, KOL’s views, Analyst’s views, Anticoagulants Market Access and Reimbursement

To know more about Anticoagulants companies working in the treatment market, visit @ Anticoagulants Clinical Trials and Therapeutic Assessment

Table of Contents

1. Anticoagulants Market Report Introduction

2. Executive Summary for Anticoagulants

3. SWOT analysis of Anticoagulants

4. Anticoagulants Patient Share (%) Overview at a Glance

5. Anticoagulants Market Overview at a Glance

6. Anticoagulants Disease Background and Overview

7. Anticoagulants Epidemiology and Patient Population

8. Country-Specific Patient Population of Anticoagulants

9. Anticoagulants Current Treatment and Medical Practices

10. Anticoagulants Unmet Needs

11. Anticoagulants Emerging Therapies

12. Anticoagulants Market Outlook

13. Country-Wise Anticoagulants Market Analysis (2019–2032)

14. Anticoagulants Market Access and Reimbursement of Therapies

15. Anticoagulants Market Drivers

16. Anticoagulants Market Barriers

17. Anticoagulants Appendix

18. Anticoagulants Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anticoagulants Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Takeshi Morimoto, Prothya BioSolutions, ARYx Therapeutics, Les Laboratoires